Physician profile
Nan Ni
NPI 1518926500
$2,693.33
in general payments reported to CMS, 2019-2025
14 companies · $185 in 2025
The $185 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $251 · 2021: $224 · 2022: $282 · 2023: $183 · 2024: $208 · 2025: $185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $735.82 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $523.76 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $293.63 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $285.60 | 2019-2023 | |
| Lilly USA, LLC | $225.01 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $173.03 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.91 | 2022-2023 | |
| Abbott Laboratories | $86.64 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.00 | 2019 | |
| Exact Sciences Corporation | $61.62 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $40.42 | 2019 | |
| Glaxosmithkline, LLC. | $28.62 | 2020-2022 | |
| Amgen INC. | $23.55 | 2024 | Krystexxa |
| Janssen Pharmaceuticals, INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nan Ni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.